Lipid peroxidation and impaired vascular function in patients with type 1 diabetes mellitus
- 10 Downloads
Abstract
Patients with type 1 diabetes mellitus (T1DM) develop microvascular complications during the course of the disease. Oxidative stress is the main mechanism of the microvascular damage. Currently no specific and reliable laboratory tests are available for screening of early microvascular changes. 56 patients with T1DM were included. We measured their serum levels of malonyl dialdehyde and reactive aldehydes with chain lengths C6–C12, which are known to be generated during lipid peroxidation, a process associated with oxidative stress. Serum levels of aldehydes were compared with the parameters of microvascular reactivity (MVR) examined by laser Doppler flowmetry and with the parameters of blood glucose control (glycated hemoglobin, glycemic variability using continuous glucose monitoring). In this cross-sectional observational study, higher levels of reactive aldehydes were associated with impaired skin MVR in T1DM. However, the parameters of glucose control were not associated with lipid peroxidation or MVR in our study. Therefore, we suggest that other than simple glycemic mechanism may be more important in the process of reactive aldehyde generation in T1DM.
Graphical abstract
Keywords
Oxidative stress Diabetes mellitus Aldehydes Carbohydrates RadicalsNotes
Acknowledgements
This work was partially funded by Research Project Progres Q25/LF1 and Grant 15-26705A of the Agency for Healthcare Research (AZV) of the Czech Republic.
References
- 1.Giacco F, Brownlee M (2010) Circ Res 107:1058CrossRefGoogle Scholar
- 2.Skrha J, Soupal J, Skrha J Jr, Prazny M (2016) Rev Endocr Metab Disord 17:103CrossRefGoogle Scholar
- 3.Kuricova K, Pacal L, Soupal J, Prazny M, Kankova K (2016) Diabetes Res Clin Pract 114:1CrossRefGoogle Scholar
- 4.The Diabetes Control and Complications Trial Research Group (1993) N Engl J Med 329:977CrossRefGoogle Scholar
- 5.Hirsch IB, Brownlee M (2005) J Diabetes Complications 19:178CrossRefGoogle Scholar
- 6.Soupal J, Skrha J Jr, Gajmon M, Horova E, Mraz M, Skrha J, Prazny M (2014) Diabetes Technol Ther 16:198CrossRefGoogle Scholar
- 7.Pena AS, Couper JJ, Harrington J, Gent R, Fairchild J, Tham E, Baghurst P (2012) Diabetes Technol Ther 14:457CrossRefGoogle Scholar
- 8.Service FJ (2013) Diabetes 65:1398CrossRefGoogle Scholar
- 9.Fuchs D, Dupon PP, Schaap LA, Drailer R (2017) Cardiovasc Diabetol 16:11CrossRefGoogle Scholar
- 10.Babos L, Jarai Z, Nemcsik J (2013) World J Nephrol 2:77CrossRefGoogle Scholar
- 11.Antus B (2016) Oxid Med Cell Longev 2016:2930434CrossRefGoogle Scholar
- 12.Fatima N, Faisal SM, Zubair S, Ajmal M, Siddiqui SS, Moin S, Owais M (2016) PLoS ONE 11:e0161548CrossRefGoogle Scholar
- 13.Horova E, Pelcl T, Soupal J, Skrha J Jr, Flekac M, Vejrazka M, Skrha J, Prazny M (2018) Diabetes Res Clin Pract 139:300CrossRefGoogle Scholar
- 14.Syslova K, Bohmova A, Mikoska M, Kuzma M, Pelclova D, Kacer P (2014) Oxid Med Cell Longev 2014:562860CrossRefGoogle Scholar
- 15.Pelclova D, Fenclova Z, Kacer P, Kuzma M, Navratil T, Lebedova J (2008) Ind Health 46:484CrossRefGoogle Scholar
- 16.Syslova K, Kacer P, Kuzma M, Najmonova V, Fenclova Z, Vlckova S, Lebedova J, Pelclova D (2009) J Chromatogr B Analyt Technol Biomed Life Sci 877:2477CrossRefGoogle Scholar
- 17.Pelclova D, Zdimal V, Kacer P, Fenclova Z, Vlckova S, Syslova K, Navratil T, Schwarz J, Zikova N, Barosova H, Turci F, Komarc M, Pelcl T, Belacek J, Kukutschova J, Zakharov S (2016) J Breath Res 10:016004CrossRefGoogle Scholar
- 18.Pelcl T, Skrha J Jr, Prazny M, Vlckova S, Fenclova Z, Navratil T, Malik J, Diblik P, Zikan V, Pelclova D (2018) Basic Clin Pharmacol Toxicol 123:356CrossRefGoogle Scholar
- 19.Pelclova D, Navratil T, Vlckova S, Fenclova Z, Pelcl T, Kacerova T, Kacer P (2018) Monatsh Chem 149:1579CrossRefGoogle Scholar
- 20.Pelclova D, Prazny M, Skrha J, Fenclova Z, Kalouskova M, Urban P, Navratil T, Senholdova Z, Smerhovsky Z (2007) Hum Exp Toxicol 26:705CrossRefGoogle Scholar